How an Unproven Alzheimer's Drug Got Approved
https://www.nytimes.com/2021/07/19/health/alzheimers-drug-aduhelm-fda.html
How an Unproven Alzheimers Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogens Aduhelm, or aducanumab.
By Pam Belluck, Sheila Kaplan and Rebecca Robbins
Published July 19, 2021 Updated July 20, 2021, 8:51 a.m. ET
Two months before the Food and Drug Administrations deadline to decide whether to approve Biogens controversial Alzheimers drug aducanumab, a council of senior agency officials resoundingly agreed that there wasnt enough evidence it worked.
The session, whose details have not been reported before, represented at least the third time that proponents of approving aducanumab in the F.D.A. had received a clear message that the evidence did not convincingly show the drug could slow cognitive decline.
On June 7, the F.D.A. greenlighted the drug anyway a decision that has been met with scathing rebuke from many Alzheimers experts and other scientists and calls for investigations into how the agency approved a treatment that has little evidence it helps patients.
How and why the F.D.A. went ahead and approved the drug an intravenous infusion, marketed as Aduhelm, that the company has since priced at $56,000 a year has become the subject of intense scrutiny. Two congressional committees are investigating the approval and the price. Much is still unknown, but an examination by The Times has found that the process leading to approval took several unusual turns, including a decision for the F.D.A. to work far more closely with Biogen than is typical in a regulatory review.